Slide 1: Article summary: NeuroRestore ACD856
Article summary December 2024 NeuroRestore ACD856 Positive Allosteric Modulator of Trk- receptors for the Treatment of Alzheimer’s Disease 1 12/30/2024
Slide 2: Summary of a scientific article published in Pharmaceuticals in 2024
Summary of a scientific article published in Pharmaceuticals in 2024 2 Link to article: https://www.mdpi.com/1424-8247/17/8/997
Slide 3: Neurotrophins and their signaling
Neurotrophins and their signaling • The neurotrophins Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) are key for brain health and cognition • BDNF & NGF signaling are implicated in several key neuronal functions, including cholinergic function, hippocampal neurogenesis and sy
Slide 4: Expression of Trk-receptors in the human brain
Expression of Trk-receptors in the human brain Trk-receptors are expressed in discrete regions of the human brain 4
Slide 5: ACD856 – Symptomatic Effects with Potential for Disease Modification
ACD856 – Symptomatic Effects with Potential for Disease Modification Neurotrophins: NGF, BDNF, NT-3 and NT-4/5 ACD856: A pan-Trk positive allosteric Receptors: modulator leading to: TrkA, TrkB and TrkC • Increased receptor activity Short term effects: • Increased synaptic function • Phosphorylation
Slide 6: Two examples of successful discovery and development of PAMs
Two examples of successful discovery and development of PAMs are the TrkA-PAM E2511 and the pan-Trk PAM ACD856. Eisai E2511 AlzeCure ACD856 Mechanism of Action Positive allosteric modulator Positive allosteric modulator Target TrkA TrkA, TrkB and TrkC Type Novel small molecule (<400 Da) Novel small
Slide 7: A schematic representation of biomarkers and clinical course of Alzheimer's disease
A schematic representation of biomarkers and clinical course of Alzheimer’s disease ACD856 could potentially be used both as a symptomatic treatment but also as disease-modifying treatment earlier in the disease progression 7
Slide 8: Schematic view of different possible therapeutic modalities on Alzheimer's disease progression
Schematic view of different possible therapeutic modalities on Alzheimer’s disease progression A symptomatic treatment with disease-modifying properties could change the disease progression 8
Slide 9: Summary
Summary 1. Neurotrophins and their receptors are important for both neuronal and non-neuronal function 2. Trk-receptors are expressed in different regions of the brain 3. Two different small molecule positive allosteric modulators of Trk-receptors are in clinical development, i.e. Eisai’s E2511 and
Slide 10: AlzeCure Pharma AB
AlzeCure Pharma AB Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm Sweden www.alzecurepharma.com info@alzecurepharma.com CONFIDENTIAL